Bispecific monoclonal antibody

Compugen to Participate in the Stifel Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022
NASDAQ, TIGIT, Investor relations, Company, TEL, Bispecific monoclonal antibody, Conference, Nasdaq, Compugen, AstraZeneca, Research, CEO, Pharmaceutical industry, Bayer

HOLON, ISRAEL, Nov. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapycompany and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team will participate in a fireside chat at the upcoming Stifel 2022 Healthcare Conference in New York City.

Key Points: 
  • HOLON, ISRAEL, Nov. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapycompany and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team will participate in a fireside chat at the upcoming Stifel 2022 Healthcare Conference in New York City.
  • The fireside chat will take place on Tuesday, November 15, 2022 at 9:10am ET.
  • A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com .
  • Compugenis headquartered in Israel, with offices in South San Francisco, CA.Compugen'sshares are listed on Nasdaq and the Tel AvivStock Exchange under the ticker symbol CGEN.

Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Congress, Patient, Annual report, Research, Therapy, 2021 Essex County Council election, Cancer, Human, Society for Immunotherapy of Cancer, Bispecific monoclonal antibody, FDA, Safety, Abstract, COVID-19, Marketing, Immunotherapy, Annual general meeting, PD-L1, U.S. Securities and Exchange Commission, Small molecule, Hematology, Security (finance), Society, EST, SITC, Trial of the century, Solution, Pharmaceutical industry, Incyte

Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually.
  • We look forward to presenting data at the SITC Annual Meeting from our immuno-oncology pipeline, including our oral PD-L1 program, as we make progress toward our goal of identifying new solutions for patients with cancer who need additional options.
  • All accepted odd-numbered posters are available from 9:00 a.m. 9:00 p.m. EST on Thursday, November 10.
  • The virtual meeting platform will be available following the conclusion of the meeting for registered attendees until Monday, Jan. 9, 2023.

Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients

Retrieved on: 
Monday, November 7, 2022
Private Securities Litigation Reform Act, Tumor microenvironment, Drug discovery, Ovarian cancer, FDA, Compugen, Population, Securities Exchange Act of 1934, Research, Annual report, U.S. Securities and Exchange Commission, ET, SEC, SITC, Company, Journal, B cell, Immunotherapy, Securities Act of 1933, Forward-looking statement, TLS, Security (finance), Society, Patient, Cancer, TIGIT, SVP, Nivolumab, DC, PVRL2, Neoplasm, Terminology, COVID-19, AstraZeneca, Society for Immunotherapy of Cancer, Risk, JITC, Q3, Compugen (Israeli company), Safety, TME, Poster, Nasdaq, Countersurveillance, TEL, Platinum, Bispecific monoclonal antibody, PD-1, NASDAQ, Drug Quality and Security Act, Vaccine, Pharmaceutical industry, Bayer, PVRIG

In addition to the data in the abstract, the Friday oral presentation will include new translational data from a number of platinum resistant ovarian cancer patients treated with COM701 monotherapy and from the fully enrolled MSS-CRC COM701 and nivolumab cohort.

Key Points: 
  • In addition to the data in the abstract, the Friday oral presentation will include new translational data from a number of platinum resistant ovarian cancer patients treated with COM701 monotherapy and from the fully enrolled MSS-CRC COM701 and nivolumab cohort.
  • "I believe the data we will present at SITC support the potential of PVRIG to open new possibilities in cancer immunotherapy," said Dr. Eran Ophir.
  • "The translational data are exciting because they support the anti-tumor activity we have shown with COM701 in combination with nivolumab in patients with MSS-CRC typically not responsive to approved checkpoint inhibitors.
  • Peripheral immune modulation was also seen with COM701 alone in a platinum resistant ovarian cancer patient with a partial response."

Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Thursday, November 3, 2022
FDA, Fitness & Nutrition, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Patient, Science, Medicines and Healthcare products Regulatory Agency, Society, EMA, PRIME, European Medicines Agency, FDA, CD3, YouTube, U.S. Securities and Exchange Commission, Clinical trial, Disease, Melanoma, B-cell maturation antigen, Food, NYSE, SC, Breakthrough, Multiple myeloma, ASH, RRMM, Vaccine, Cancer, Blood, ORR, Research, Bone marrow, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough therapy, Breast, COVID-19, CCO, Bispecific monoclonal antibody, PFE, B cell, Hematology, Antigen, Immunotherapy, Survival, News, Lymphatic system, BCMA, Antibody, Probability, Inc., Cytokine release syndrome, Safety, CRS, Orphan, MHRA, Innovative Medicines Initiative, Risk, Causality, ASCO, Pharmaceutical industry, Medical device, Pfizer

Pfizer Inc. (NYSE:PFE) today announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM).

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM).
  • This marks Pfizers twelfth FDA Breakthrough Therapy Designation in Oncology, a testament to our relentless commitment to developing transformational cancer medicines in areas of high unmet need.
  • In addition to the Breakthrough Therapy Designation, elranatamab has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for the treatment of MM.
  • The FDA and EMA have granted elranatamab Fast Track Designation and the PRIME scheme, respectively, for the treatment of patients with RRMM.

Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022

Retrieved on: 
Monday, October 31, 2022
Compugen, Annual general meeting, TEL, Research, Immunotherapy, Society, Bispecific monoclonal antibody, Company, Telephone, TIGIT, AstraZeneca, Nasdaq, Pharmaceutical industry, Broadcasting, Bayer, Cancer

HOLON, Israel, Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open.

Key Points: 
  • HOLON, Israel, Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open.
  • Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
  • As part of the update, management will discuss Compugen's data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-12, 2022.
  • To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
    or +972-3-918-0644 internationally.

Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 26, 2022
University of California, Irvine School of Medicine, Therapy, SEC, Patent, University, Security (finance), U.S. Securities and Exchange Commission, AE, Private Securities Litigation Reform Act, Safety, Cancer, Investor, Immunoglobulin G, Large-cell lung carcinoma, TKI, Neoplasm, Webcast, Poster, Department, Division, IRR, ADCC, Program, Patient, EGFR, GLOBE, NSCLC, COVID-19, HNSCC, AES, Name, Hematology-Oncology and Stem Cell Transplantation Research Center, CET, Bispecific monoclonal antibody, Meru Networks, Pharmaceutical industry, Vaccine

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of interim data as of an August 15, 2022 data cutoff, from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129, on the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA Symposium) website. MCLA-129 is a fully human ADCC enhanced IgG1 Biclonics® bispecific antibody that binds to EGFR and c-MET and is being investigated in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. This phase 1/2 study has completed the dose escalation phase and is on-going in the dose expansion phase.

Key Points: 
  • This phase 1/2 study has completed the dose escalation phase and is on-going in the dose expansion phase.
  • The poster is now available on the Merus website and will be presented at the 34th ENA Symposium in Barcelona, Spain on Friday, October 28, 2022, 10:00-15:00 CET.
  • Preclinical data have shown that MCLA-129 can effectively treat TKI-resistant non-small cell lung cancer (NSCLC) in xenograft models of cancer.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics.

Compugen to Present New Clinical Data at ESMO-IO

Retrieved on: 
Wednesday, October 26, 2022
TIGIT, AstraZeneca, Platinum, Compugen, Compugen (Israeli company), Patient, Research, Bispecific monoclonal antibody, Nasdaq, European Society for Medical Oncology, Oncology, Company, NSCLC, Nivolumab, TEL, Congress, Ovarian cancer, Pharmaceutical industry, Bayer

HOLON, Israel, Oct. 26, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapycompany and a pioneer in computational target discovery, announced todaythat it will present new clinical data from its COM701/nivolumab with or without BMS-986207 combination studies in patients with platinum resistant ovarian cancer and data from COM701 with or without nivolumab study in patients with metastatic NSCLC as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland.

Key Points: 
  • HOLON, Israel, Oct. 26, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapycompany and a pioneer in computational target discovery, announced todaythat it will present new clinical data from its COM701/nivolumab with or without BMS-986207 combination studies in patients with platinum resistant ovarian cancer and data from COM701 with or without nivolumab study in patients with metastatic NSCLC as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland.
  • Compugen's presentations will be available on the publications section of Compugen's website, www.cgen.com following presentation.
  • The most advanced program, COM503 is about to enter pre-IND enabling studies.COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner.
  • Compugenis headquartered in Israel, with offices in South San Francisco, CA.Compugen'sshares are listed on Nasdaq and the Tel AvivStock Exchange under the ticker symbol CGEN.

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

Retrieved on: 
Monday, October 17, 2022
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Protein engineering, Therapy, CRS, SEC, Medicine, Risk, Acute myeloid leukemia, AML, DART, CD3, Cytokine release syndrome, NASDAQ, Microdeletion syndrome, MDS, Biotechnology, Patient, Lymphatic system, Research, Twitter, Security (finance), Program, Bispecific monoclonal antibody, Multimedia, Investment, Partnership, Gilead Sciences, Senior, Cancer, Private Securities Litigation Reform Act, HIV, EPS, CD123, Exercise, MD, Doctor of Philosophy, Industry, Science, Blood, Lists of disasters, Toxicity, CEO, Macrogen, GILD, IPR, COVID-19, Half-life, Pharmaceutical industry

Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.

Key Points: 
  • Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.
  • View the full release here: https://www.businesswire.com/news/home/20221016005052/en/
    A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics.
  • MacroGenics bispecific expertise naturally complements Gileads portfolio strengths in immuno-oncology and our growing hematology franchise, said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences.
  • Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 12, 2022
Immunoglobulin G, U.S. Securities and Exchange Commission, CET, EGFR, Therapy, SEC, Webcast, Investor, Neoplasm, IRR, ENA, Patient, Poster, Division, Bispecific monoclonal antibody, Program, Security (finance), Cancer, Private Securities Litigation Reform Act, Hematology-Oncology and Stem Cell Transplantation Research Center, University, Meru Networks, NSCLC, Department, Large-cell lung carcinoma, Patent, GLOBE, COVID-19, University of California, Irvine School of Medicine, Name, TKI, Online gambling, Pharmaceutical industry, Vaccine

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 on the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA Symposium) website. MCLA-129 is a fully human IgG1 Biclonics® bispecific antibody that binds to EGFR and c-MET and is being investigated in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. This phase 1/2 study has completed the dose escalation phase and is on-going in the dose expansion phase.

Key Points: 
  • This phase 1/2 study has completed the dose escalation phase and is on-going in the dose expansion phase.
  • The poster will be presented at the 34th ENA Symposium in Barcelona, Spain on Friday, October 28, 2022, 10:00-15:00 CET, and will be available online Wednesday, October 26, 2022.
  • Preclinical data have shown that MCLA-129 can effectively treat TKI-resistant non-small cell lung cancer (NSCLC) in xenograft models of cancer.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics .

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Retrieved on: 
Tuesday, September 27, 2022
PR, Bispecific monoclonal antibody, Breast, Path integral molecular dynamics, Granulosa cell tumour, Woman, Twitter, Lehr, Food, IND, Intention, LinkedIn, Company, MBCA, Private Securities Litigation Reform Act, Context, Therapy, Forward-looking statement, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Cancer, U.S. Securities and Exchange Commission, Breast cancer, CEO, Endometrial cancer, Female, CLDN6, Nasdaq, Climate, SERD, New Drug Application, Biotechnology, GLOBE, CD3, Pharmaceutical industry

PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecological cancers,today announced updated cash guidance to extend its runway into Q1 2024.

Key Points: 
  • PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecological cancers,today announced updated cash guidance to extend its runway into Q1 2024.
  • Context has been fortunate to collaborate with two tremendous organizations The Menarini Group and Integral Molecular.
  • Context Therapeutics Inc. (Nasdaq: CNTX)is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers.
  • Context is also developing a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development.